Vas Narasimhan joins the Anthropic board: AI and health | Keryc
Vas Narasimhan, a physician-scientist and CEO of Novartis, was named by the Anthropic Long-Term Benefit Trust as a new member of Anthropic's board. Why does this matter beyond a change on a plaque? Because it brings together two worlds: the regulated health industry and the development of responsible artificial intelligence.
What his appointment means
Anthropic is a Public Benefit Corporation, and its governance aims to balance financial success with a public purpose: developing AI for the benefit of humanity. The Long-Term Benefit Trust is an independent body with no direct financial stake in the company and has the authority to appoint directors to ensure that balance.
With Narasimhan's arrival, directors appointed by the Trust now form the majority of the board. That changes the governance dynamics: the voice that watches over long-term benefit gains weight against other pressures. Does that sound important? It is, especially if you think about technology that can influence public health.
What Narasimhan brings and why he was chosen
Vas Narasimhan has led the development and approval of more than 35 novel medicines at Novartis, in one of the most regulated industries in the world. That gives him practical experience taking complex innovations from idea to patient, while meeting regulations and managing risks.
Daniela Amodei, cofounder and chair of Anthropic, highlights that same point: the ability to bring powerful technology to people safely and at scale. Neil 'Buddy' Shah, chair of the Trust, sums up the expectation: Narasimhan brings the perspective of someone who has worked to deploy high‑impact science responsibly.
Health, equity, and the promise of AI
Narasimhan talks about how AI is accelerating hard problems in health: from better understanding disease biology to designing more effective medicines. His background also includes early work on HIV, malaria, and tuberculosis programs in India, Africa, and South America, and an ongoing commitment to global access and public health priorities.
Why does that matter for you? Because AI in health is not just a technical advance; it involves choices about equity, privacy, regulation, and access. Having someone on the board who knows those dilemmas from clinical practice and regulatory management helps ensure product and deployment decisions consider real patients.
Who is on the board now
Narasimhan joins a board that includes Dario Amodei, Daniela Amodei, Yasmin Razavi, Jay Kreps, Reed Hastings, and Chris Liddell. The majority of directors are now appointed by the Trust, reinforcing the public mission in governance.
Final thought
This isn't just a high‑profile hire; it's a sign that Anthropic is prioritizing health expertise and responsible governance as it builds AI with real-world impact. If you're curious about how AI will affect medicine and public policy, this move matters: it shows how AI companies are building bridges between technological innovation and social responsibility.
